Blood–Brain Barrier Disruption Is Not Associated With Disease Aggressiveness in Amyotrophic Lateral Sclerosis
The pathogenesis of the fatal neurodegenerative condition amyotrophic lateral sclerosis (ALS) remains to be fully understood. Blood–brain barrier damage (BBBD) has been implicated as an exacerbating factor in several neurodegenerative conditions, including ALS. Therefore, this cross-sectional study...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-10-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2021.656456/full |
| _version_ | 1830360433337303040 |
|---|---|
| author | Tino Prell Benjamin Vlad Nayana Gaur Beatrice Stubendorff Julian Grosskreutz Julian Grosskreutz |
| author_facet | Tino Prell Benjamin Vlad Nayana Gaur Beatrice Stubendorff Julian Grosskreutz Julian Grosskreutz |
| author_sort | Tino Prell |
| collection | DOAJ |
| description | The pathogenesis of the fatal neurodegenerative condition amyotrophic lateral sclerosis (ALS) remains to be fully understood. Blood–brain barrier damage (BBBD) has been implicated as an exacerbating factor in several neurodegenerative conditions, including ALS. Therefore, this cross-sectional study used the novel D50 progression model to assess the clinical relevance of BBBD within a cohort of individuals with either ALS (n = 160) or ALS mimicking conditions (n = 31). Routine laboratory parameters in cerebrospinal fluid (CSF) and blood were measured, and the ratio of CSF to serum albumin levels (Qalb) was used as a proxy measure of BBBD. In the univariate analyses, Qalb levels correlated weakly with disease aggressiveness (as indicated by individual D50 values) and physical function (as measured by ALS Functional Rating Scale). However, after adjustment for cofactors in the elastic net regularization, only having limb-onset disease was associated with BBBD. The results reported here emphasize the clinical heterogeneity of ALS and the need for additional longitudinal and multi-modal studies to fully clarify the extent and effect of BBBD in ALS. |
| first_indexed | 2024-12-20T03:16:34Z |
| format | Article |
| id | doaj.art-7fc5b1278b2e4d139b85e96845284bce |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-12-20T03:16:34Z |
| publishDate | 2021-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-7fc5b1278b2e4d139b85e96845284bce2022-12-21T19:55:20ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2021-10-011510.3389/fnins.2021.656456656456Blood–Brain Barrier Disruption Is Not Associated With Disease Aggressiveness in Amyotrophic Lateral SclerosisTino Prell0Benjamin Vlad1Nayana Gaur2Beatrice Stubendorff3Julian Grosskreutz4Julian Grosskreutz5Department of Geriatrics, Halle University Hospital, Jena, GermanyDepartment of Neurology, Jena University Hospital, Jena, GermanyDepartment of Neurology, Jena University Hospital, Jena, GermanyDepartment of Neurology, Jena University Hospital, Jena, GermanyDepartment of Neurology, Jena University Hospital, Jena, GermanyPrecision Neurology, University of Lüebeck, Lüebeck, GermanyThe pathogenesis of the fatal neurodegenerative condition amyotrophic lateral sclerosis (ALS) remains to be fully understood. Blood–brain barrier damage (BBBD) has been implicated as an exacerbating factor in several neurodegenerative conditions, including ALS. Therefore, this cross-sectional study used the novel D50 progression model to assess the clinical relevance of BBBD within a cohort of individuals with either ALS (n = 160) or ALS mimicking conditions (n = 31). Routine laboratory parameters in cerebrospinal fluid (CSF) and blood were measured, and the ratio of CSF to serum albumin levels (Qalb) was used as a proxy measure of BBBD. In the univariate analyses, Qalb levels correlated weakly with disease aggressiveness (as indicated by individual D50 values) and physical function (as measured by ALS Functional Rating Scale). However, after adjustment for cofactors in the elastic net regularization, only having limb-onset disease was associated with BBBD. The results reported here emphasize the clinical heterogeneity of ALS and the need for additional longitudinal and multi-modal studies to fully clarify the extent and effect of BBBD in ALS.https://www.frontiersin.org/articles/10.3389/fnins.2021.656456/fullneurodegenerationblood-brain barrierinflammationamyotrophic lateral sclerosis (ALS)disease aggressiveness |
| spellingShingle | Tino Prell Benjamin Vlad Nayana Gaur Beatrice Stubendorff Julian Grosskreutz Julian Grosskreutz Blood–Brain Barrier Disruption Is Not Associated With Disease Aggressiveness in Amyotrophic Lateral Sclerosis Frontiers in Neuroscience neurodegeneration blood-brain barrier inflammation amyotrophic lateral sclerosis (ALS) disease aggressiveness |
| title | Blood–Brain Barrier Disruption Is Not Associated With Disease Aggressiveness in Amyotrophic Lateral Sclerosis |
| title_full | Blood–Brain Barrier Disruption Is Not Associated With Disease Aggressiveness in Amyotrophic Lateral Sclerosis |
| title_fullStr | Blood–Brain Barrier Disruption Is Not Associated With Disease Aggressiveness in Amyotrophic Lateral Sclerosis |
| title_full_unstemmed | Blood–Brain Barrier Disruption Is Not Associated With Disease Aggressiveness in Amyotrophic Lateral Sclerosis |
| title_short | Blood–Brain Barrier Disruption Is Not Associated With Disease Aggressiveness in Amyotrophic Lateral Sclerosis |
| title_sort | blood brain barrier disruption is not associated with disease aggressiveness in amyotrophic lateral sclerosis |
| topic | neurodegeneration blood-brain barrier inflammation amyotrophic lateral sclerosis (ALS) disease aggressiveness |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2021.656456/full |
| work_keys_str_mv | AT tinoprell bloodbrainbarrierdisruptionisnotassociatedwithdiseaseaggressivenessinamyotrophiclateralsclerosis AT benjaminvlad bloodbrainbarrierdisruptionisnotassociatedwithdiseaseaggressivenessinamyotrophiclateralsclerosis AT nayanagaur bloodbrainbarrierdisruptionisnotassociatedwithdiseaseaggressivenessinamyotrophiclateralsclerosis AT beatricestubendorff bloodbrainbarrierdisruptionisnotassociatedwithdiseaseaggressivenessinamyotrophiclateralsclerosis AT juliangrosskreutz bloodbrainbarrierdisruptionisnotassociatedwithdiseaseaggressivenessinamyotrophiclateralsclerosis AT juliangrosskreutz bloodbrainbarrierdisruptionisnotassociatedwithdiseaseaggressivenessinamyotrophiclateralsclerosis |